Maze Therapeutics (MAZE), a clinical stage biopharma focused on kidney and metabolic diseases, has drawn investor attention after recent share price swings and a one-year total return figure that stands in sharp contrast to its recent negative short-term moves.

Recent trading has been choppy, with a 1 month share price return showing a 37.66% decline and a year to date share price return showing a 29.37% decline. However, the 1 year total shareholder return of 252.45% highlights how strong earlier gains were and suggests that momentum has faded in the short term even as longer term holders remain well ahead.

If Maze’s recent volatility has you thinking about what else is moving in healthcare, it could be a good time to scan for other clinical and AI driven names using our 34 healthcare AI stocks

So with a 252.45% one year total return, recent double digit pullbacks, and a last close of US$28.09 versus an analyst target of US$64.82, is MAZE now undervalued, or is the market already pricing in future growth?

Price to Book of 3.9x: Is it justified?

Maze Therapeutics trades on a P/B of 3.9x, which sits above both its direct peers and the broader US pharmaceuticals group at the current share price of $28.09.

P/B compares a company’s market value to its net assets on the balance sheet. This can be a useful cross check for early stage, loss making drug developers where earnings are not yet a guide. A higher P/B often signals that investors are willing to pay more than the accounting value of assets, typically because they see future potential that is not yet reflected in current financials.

For Maze, this richer 3.9x P/B comes alongside no meaningful revenue reported, a net loss of $131.12m and a forecast that earnings will remain negative over the next three years, even as revenue is projected to grow quickly. That combination suggests the market is putting a premium on the clinical pipeline and future revenue expectations rather than current profitability or asset backing.

The gap to benchmarks is clear. Management’s own sector, the US pharmaceuticals industry, trades on an average P/B of 2.5x, and Maze also stands above the peer group average of 3.8x. In other words, investors are currently asked to pay more per dollar of book value for Maze than for the typical US pharma name, despite the company’s unprofitable status and reliance on higher risk funding sources.

Result: Price to book ratio of 3.9x

However, this richer P/B comes with clear risks, including continued net losses of $131.12m, as well as clinical or partnership setbacks that could quickly reset expectations.

Next Steps

Does the strong one-year return alongside recent pullbacks leave you feeling cautious or curious about what comes next? Act quickly, review the underlying numbers yourself, and then weigh the 1 key reward and 4 important warning signs

Looking for more investment ideas?

If you want to keep sharpening your watchlist, do not stop at Maze. Use screeners to surface other opportunities that fit the way you like to invest.

• Target potential mispricings by running a scan for companies flagged as 64 high quality undervalued stocks before the wider market catches on.
• Strengthen your income focus by checking out a curated list of 12 dividend fortresses that aim to combine yield with resilience.
• Zero in on quality by reviewing a solid balance sheet and fundamentals stocks screener (40 results) that could better withstand shocks and funding pressures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.